Form 8-K - Current report:
SEC Accession No. 0001641172-25-013491
Filing Date
2025-06-03
Accepted
2025-06-03 17:15:02
Documents
15
Period of Report
2025-06-03
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 44772
2 EX-99.1 ex99-1.htm EX-99.1 17156
3 GRAPHIC ex99-1_001.jpg GRAPHIC 2991
  Complete submission text file 0001641172-25-013491.txt   287751

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE bfri-20250603.xsd EX-101.SCH 3975
5 XBRL DEFINITION FILE bfri-20250603_def.xml EX-101.DEF 26989
6 XBRL LABEL FILE bfri-20250603_lab.xml EX-101.LAB 37209
7 XBRL PRESENTATION FILE bfri-20250603_pre.xml EX-101.PRE 25609
17 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 6815
Mailing Address 120 PRESIDENTIAL WAY, SUITE 330 WOBURN MA 01801
Business Address 120 PRESIDENTIAL WAY, SUITE 330 WOBURN MA 01801 781-245-1325
Biofrontera Inc. (Filer) CIK: 0001858685 (see all company filings)

EIN.: 473765675 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40943 | Film No.: 251020798
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)